Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
In brief
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Key facts
- Study ID
- NCT06276491
- Run by
- Xencor, Inc.
- People needed
- 282
- Starts
- 2024-04-04
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-06-11
Who can join
Age: 15 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- Stanford — Palo Alto, California, United States (enrolling)
- University of California — San Francisco, California, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
- University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
- The John Theruer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York, United States (enrolling)
- The Ohio State University — Columbus, Ohio, United States (enrolling)
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (enrolling)
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- University of Virginia — Charlottesville, Virginia, United States (enrolling)
- Herlev Gentofte Hospital — Herlev, Denmark
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.